Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

You may be eligible if

• Previously enrolled in the Betaseron pivotal study protocols TB01-35686 in the US and TB01-35886 in Canada (total, N=372)
• Patient, caregiver, or legal guardian must provide written informed consent
• Patient must confirm her/his ability and agreement to participate in the study at the beginning of the phone call